Vanguard Group
DICE

Vanguard Group’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Vanguard Group’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,957,417
Closed -$90.9M – 4605
2023
Q2 		$90.9M Buy
1,957,417
+29,161
+2% +$1.01M ﹤0.01% 1906
2023
Q1 		$55.2M Buy
1,928,256
+24,840
+1% +$736K ﹤0.01% 2132
2022
Q4 		$59.4M Buy
1,903,416
+516,658
+37% +$16.8M ﹤0.01% 2095
2022
Q3 		$28.1M Buy
1,386,758
+170,649
+14% +$3.11M ﹤0.01% 2477
2022
Q2 		$18.9M Buy
1,216,109
+619,476
+104% +$10.7M ﹤0.01% 2667
2022
Q1 		$11.4M Buy
596,633
+14,313
+2% +$255K ﹤0.01% 3079
2021
Q4 		$14.7M Buy
+582,320
New +$17.1M ﹤0.01% 3005

Vanguard Group's DICE Position: Q3 2023 in Review

Vanguard Group sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 1,957,417 shares — an estimated $90.9M sold.

Vanguard Group first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $90.9M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

  • Vanguard Group reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Vanguard Group sold 1,957,417 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $90.9M.
  • Vanguard Group first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
  • Vanguard Group's DICE Therapeutics, Inc. Common Stock position peaked at $90.9M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Vanguard Group's 13F filing for Q3 2023, filed 14 Nov 2023.